The complement system, which is made up of more than 30 serum and cell surface components, works with the innate and acquired immune systems to recognize and get rid of pathogens. Following the activation of the complement system, a series of events involving proteolysis and assembly lead to the cleavage of the third complement component (C3). The activation pathway refers to the cascade that leads to C3 cleavage. The classical, lectin, and alternative pathways are the three types of activation.
The complement cascade is a double-edged sword that causes phagocytosis and inflammation while also providing defense against viral and bacterial invasion. If complement is not properly controlled, it can cause significant pathological damage to erythrocytes (hemolysis), kidney basement membrane and attached endothelial and epithelial cells (nephritis), joint synovium (arthritis), and blood vessels (vasculitis).
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V74800 | Pozelimab (REGN3918) | 2096328-94-6 | Pozelimab (REGN3918; Veopoz) is a human IgG4 anti-component 5 C5 monoclonal antibody (mAb). |
|
V74783 | Ravulizumab (ALXN1210) | 1803171-55-2 | Ravulizumab (ALXN1210) is a humanized monoclonal antibody (mAb) that specifically binds human complement protein C5 with high affinity. |
|
V74797 | Riliprubart (SAR 445088) | 2756228-76-7 | Riliprubart (SAR445088) is an anti-C1s humanized monoclonal antibody (mAb) that can inhibit activated C1s in the proximal part of the classical complement system. |
|
V4614 | SB290157 trifluoroacetate | 1140525-25-2 | SB290157 TFA, the trifluoroacetate salt ofSB-290157, is a novel, potent and selective antagonist of complement anaphylatoxin C3a receptor (IC50 = 200 nM) with the potential to be used in arthritis,diet-induced obesity, and metabolic dysfunction. |
|
V74784 | Tesidolumab (LFG316; Anti-Human C5 Recombinant Antibody) | 1531594-08-7 | Tesidolumab (LFG316) is a fully human IgG1/λ anti-c5 monoclonal antibody (mAb) with a molecular weight of 143 kDa (without glycosylation). |
|
V74798 | TLQP-21 | 869988-94-3 | TLQP-21 is a VGF-derived peptide with endocrine and endocrine properties and a potent G protein-coupled receptor complement 3a receptor 1 (C3aR1) agonist (EC50= mouse TLQP-21=10.3 μM; human TLQP-21=68.8 μM). |
|
V76411 | TLQP-21 TFA | TLQP-21 TFA is a VGF-derived peptide with endocrine and endocrine properties and is a potent G protein-coupled receptor complement 3a receptor 1 (C3aR1) agonist (EC50= mouse TLQP-21=10.3 μM; human TLQP-21=68.8 μM). | |
|
V74779 | Vemircopan (ALXN2050; ACH 0145228; ACH-5228) | 2086178-00-7 | Vemircopan (ALXN2050) is an orally bioactive complement factor D (FD) inhibitor. |
|
V74777 | Vesencumab (MNRP-1685A) | 1205533-60-3 | Vesencumab (MNRP-1685A) is an IG1 antibody directed against neuropilin-1 (NRP-1). |
|
V74781 | Zilucoplan (RA101495; RA3193) | 1841136-73-9 | Zilucoplan (RA101495; Zilbrysq)) is a 15-amino-acid macrocyclic peptide that is a potent inhibitor of complement component 5 (C5). |
|
V81774 | Zilucoplan TFA (RA101495 TFA; RA3193 TFA) | Zilucoplan TFA (RA101495; Zilbrysq) is a 15-amino-acid macrocyclic peptide that is a potent inhibitor of complement component 5 (C5). |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
